Full Breakdown
Boston Scientific Cuts 2026 Outlook Amid Cyberattack Fallout
By Drooid · · How we work
In this breakdown
01
Core Event: Guidance Reduction and Sales Decline
On October 28, Boston Scientific Corp. announced that its full-year adjusted earnings per share (EPS) would fall to a range of $3.16 – $3.18, down from the prior outlook of $3.28 – $3.32. The company also projected fourth-quarter net sales to decline as much as 3% year-over-year and adjusted EPS for the quarter to $0.77 – $0.79, below analysts’ expectations of $0.83. The announcement followed an August cyberattack that disrupted global operations for eight days and prompted the firm to revise its sales and earnings expectations for the full year.
02
Background & Context
The August cyber incident forced a temporary shutdown of manufacturing and supply-chain systems, which the company later quantified as a 300-basis-point hit to sales growth and a $0.07 reduction in adjusted EPS. In addition to the cyber-related impact, Boston Scientific cited pricing pressure in China—driven by a volume-based procurement program that lowers device prices—and a slowdown in its heart-device businesses, including electrophysiology and the Watchman implant.
Visual evidence
Images from the story
03
Data & Statistics
- Full-year EPS forecast: $3.16 – $3.18 (company) vs. $3.23 expected by analysts.
- Q4 EPS forecast: $0.77 – $0.79 (company) vs. $0.83 expected by analysts.
- Q4 sales outlook: decline of 1% – 3% year-over-year.
- Share price reaction: Bloomberg reported a 9% drop at 9:32 a.m.; Reuters noted a 5.3% decline by afternoon; The Motley Fool recorded a 5.84% close-day loss; TradingView cited a brief 0.4% uptick later in the session. The variance reflects differing intraday snapshots.
- Penumbra acquisition: valued at $14.5 billion, now expected to close in Q1 2027, later than originally planned due to extended regulatory review and higher financing costs.
04
Official Statements & Responses
Chief financial officer Jon Monson described 2026 as “a challenging year” and said the company has implemented a new operating model intended to improve forecasting accuracy. He added that the cycle in certain cardiovascular businesses has turned, contributing to the weaker outlook.
He also indicated that the company expects 2027 to be the trough in the cycle, with several investments and innovations slated over the next three years.
05
Conflicting Reports & Gaps
- Share-price movement: Sources differ on the magnitude and timing of the decline, ranging from a 9% intraday drop to a modest 0.4% rise later in the day. No single source provides a consolidated end-of-day figure.
- Cyberattack specifics: While the company estimates the attack cost 300 basis points in sales growth, details about the compromised systems, data loss, or remediation steps remain undisclosed.
06
Verbatim Quotes
- “We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share,” — CFO Jon Monson
07
What’s Next
Boston Scientific now targets completion of the Penumbra acquisition in Q1 2027, pending regulatory clearance and financing arrangements. The firm also expects continued top-line pressure through 2027, with a projected earnings trough that it hopes to reverse with new product investments and market-specific pricing strategies.